Histone deacetylase inhibitor-induced cellular apoptosis involves stanniocalcin-1 activation

Experimental Cell Research

Volumn 314, Issue 16, 2008, Pages 2975-2984

  Law, A Y S ^a   Lai, K P ^a   Lui, W C ^a   Wan, H T ^a   Wong, Chris K C ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

ChIP; Histone; HT29; NF B; RNA interference; Trichostatin A

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; HYPOCALCIN; LUCIFERASE; MESSENGER RNA; PARTHENOLIDE; STANNIOCALCIN 1; TRANSCRIPTION FACTOR RELA; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ACETYLATION; APOPTOSIS; ARTICLE; CELL STRAIN HT29; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GENE CONSTRUCT; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; TRANSCRIPTION REGULATION;

EID: 51649119512     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2008.07.002     Document Type: Article

References (37)

1. Chang A.C., Jellinek D.A., and Reddel R.R. Mammalian stanniocalcins and cancer. Endocr. Relat. Cancer 10 (2003) 359-373
2. Chughtai S.A., Crundwell M.C., Cruickshank N.R., Affie E., Armstrong S., Knowles M.A., Takle L.A., Kuo M., Khan N., Phillips S.M., Neoptolemos J.P., and Morton D.G. Two novel regions of interstitial deletion on chromosome 8p in colorectal cancer. Oncogene 18 (1999) 657-665
3. Armes J.E., Hammet F., de Silva M., Ciciulla J., Ramus S.J., Soo W.K., Mahoney A., Yarovaya N., Henderson M.A., Gish K., Hutchins A.M., Price G.R., and Venter D.J. Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers. Oncogene 23 (2004) 5697-5702
4. Chang A.C., Jeffrey K.J., Tokutake Y., Shimamoto A., Neumann A.A., Dunham M.A., Cha J., Sugawara M., Furuichi Y., and Reddel R.R. Human stanniocalcin (STC): genomic structure, chromosomal localization, and the presence of CAG trinucleotide repeats. Genomics 47 (1998) 393-398
5. Parniewski P., and Staczek P. Molecular mechanisms of TRS instability. Adv. Exp. Med. Biol. 516 (2002) 1-25
6. Yeung H.Y., Lai K.P., Chan H.Y., Mak N.K., Wagner G.F., and Wong C.K. Hypoxia-inducible factor-1-mediated activation of stanniocalcin-1 in human cancer cells. Endocrinology 146 (2005) 4951-4960
7. Wu S., Yoshiko Y., and De Luca F. Stanniocalcin 1 acts as a paracrine regulator of growth plate chondrogenesis. J. Biol. Chem. 281 (2006) 5120-5127
8. Lai K.P., Law A.Y., Yeung H.Y., Lee L.S., Wagner G.F., and Wong C.K. Induction of stanniocalcin-1 expression in apoptotic human nasopharyngeal cancer cells by p53. Biochem. Biophys. Res. Commun. 356 (2007) 968-975
9. Drummond D.C., Noble C.O., Kirpotin D.B., Guo Z., Scott G.K., and Benz C.C. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 495-528
10. Cress W.D., and Seto E. Histone deacetylases, transcriptional control, and cancer. J. Cell. Physiol. 184 (2000) 1-16
11. Wu S., Yoshiko Y., and De Luca F. Stanniocalcin 1 acts as a paracrine regulator of growth plate chondrogenesis. J. Biol. Chem. 281 (2006) 5120-5127
12. Chen L., Fischle W., Verdin E., and Greene W.C. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293 (2001) 1653-1657
13. Xu Y. Regulation of p53 responses by post-translational modifications. Cell Death. Differ. 10 (2003) 400-403
14. Yang X.J., and Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26 (2007) 5310-5318
15. Geiman T.M., and Robertson K.D. Chromatin remodeling, histone modifications, and DNA methylation-how does it all fit together?. J. Cell Biochem. 87 (2002) 117-125
16. Nephew K.P., and Huang T.H. Epigenetic gene silencing in cancer initiation and progression. Cancer Lett. 190 (2003) 125-133
17. Pandolfi P.P. Transcription therapy for cancer. Oncogene 20 (2001) 3116-3127
18. Timmermann S., Lehrmann H., Polesskaya A., and Harel-Bellan A. Histone acetylation and disease. Cell Mol. Life Sci. 58 (2001) 728-736
19. Glaser K.B., Staver M.J., Waring J.F., Stender J., Ulrich R.G., and Davidsen S.K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2 (2003) 151-163
20. Van Lint C., Emiliani S., and Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 5 (1996) 245-253
21. Han J.W., Ahn S.H., Kim Y.K., Bae G.U., Yoon J.W., Hong S., Lee H.Y., Lee Y.W., and Lee H.W. Activation of p21(WAF1/Cip1) transcription through Sp1 sites by histone deacetylase inhibitor apicidin: involvement of protein kinase C. J. Biol. Chem. 276 (2001) 42084-42090
22. Kim Y.K., Han J.W., Woo Y.N., Chun J.K., Yoo J.Y., Cho E.J., Hong S., Lee H.Y., Lee Y.W., and Lee H.W. Expression of p21(WAF1/Cip1) through Sp1 sites by histone deacetylase inhibitor apicidin requires PI 3-kinase-PKC epsilon signaling pathway. Oncogene 22 (2003) 6023-6031
23. Ashburner B.P., Westerheide S.D., and Baldwin Jr. A.S. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell Biol. 21 (2001) 7065-7077
24. Zhong H., May M.J., Jimi E., and Ghosh S. The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol. Cell 9 (2002) 625-636
25. Epinat J.C., and Gilmore T.D. Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway. Oncogene 18 (1999) 6896-6909
26. Hehner S.P., Hofmann T.G., Droge W., and Schmitz M.L. The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J. Immunol. 163 (1999) 5617-5623
27. Melotti P., Nicolis E., Tamanini A., Rolfini R., Pavirani A., and Cabrini G. Activation of NF-kB mediates ICAM-1 induction in respiratory cells exposed to an adenovirus-derived vector. Gene Ther. 8 (2001) 1436-1442
28. Yeung H.Y., Chan D.K., Mak N.K., Wagner G.F., and Wong C.K. Identification of signal transduction pathways that modulate dibutyryl cyclic adenosine monophosphate activation of stanniocalcin gene expression in neuroblastoma cells. Endocrinology 144 (2003) 4446-4452
29. Wu S., Yoshiko Y., and De Luca F. Stanniocalcin 1 acts as a paracrine regulator of growth plate chondrogenesis. J. Biol. Chem. 281 (2006) 5120-5127
30. Ellard J.P., McCudden C.R., Tanega C., James K.A., Ratkovic S., Staples J.F., and Wagner G.F. The respiratory effects of stanniocalcin-1 (STC-1) on intact mitochondria and cells: STC-1 uncouples oxidative phosphorylation and its actions are modulated by nucleotide triphosphates. Mol. Cell Endocrinol. 264 (2007) 90-101
31. Zhang K., Lindsberg P.J., Tatlisumak T., Kaste M., Olsen H.S., and Andersson L.C. Stanniocalcin: a molecular guard of neurons during cerebral ischemia. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 3637-3642
32. Mayo M.W., Denlinger C.E., Broad R.M., Yeung F., Reilly E.T., Shi Y., and Jones D.R. Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway. J. Biol. Chem. 278 (2003) 18980-18989
33. Tang G., Minemoto Y., Dibling B., Purcell N.H., Li Z., Karin M., and Lin A. Inhibition of JNK activation through NF-kappaB target genes. Nature 414 (2001) 313-317
34. Fan Y., Dutta J., Gupta N., Fan G., and Gelinas C. Regulation of programmed cell death by NF-kappaB and its role in tumorigenesis and therapy. Adv. Exp. Med. Biol. 615 (2008) 223-250
35. Arlt A., Gehrz A., Muerkoster S., Vorndamm J., Kruse M.L., Folsch U.R., and Schafer H. Role of NF-kappaB and Akt/PI3 K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22 (2003) 3243-3251
36. Karin M., Cao Y., Greten F.R., and Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2 (2002) 301-310
37. McCudden C.R., James K.A., Hasilo C., and Wagner G.F. Characterization of mammalian stanniocalcin receptors. Mitochondrial targeting of ligand and receptor for regulation of cellular metabolism. J. Biol. Chem. 277 (2002) 45249-45258